2 C
New York
Wednesday, February 1, 2023

Investors’ Patience Is Being Tested Right Now By MiMedx Group Inc. (NASDAQ: MDXG)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for MiMedx Group Inc. (MDXG) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.15, or -4.87%, to $2.93. The MiMedx Group Inc. has recorded 5,522 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted MIMEDX Announces Commercial Launch of EPIFIX® in Japan with Exclusive Distribution Agreement with GUNZE MEDICAL LIMITED.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Stocks Info

MiMedx Group Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Medical Devices industry. At the end of the last regular session, the stock closed at $3.08 and fluctuated between $3.1050 as its day high and $2.9000 as its day low. The current market capitalization of MiMedx Group Inc. is $345.11M. A total of 0.58 million shares were traded on the day, compared to an average of 472.31K shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, MDXG has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 10 BUYs and 23 SELLs from insiders. Insiders purchased 1,290,587 shares during that period but sold 408,782.

In the most recent transaction, Carlson Peter M sold 4,992 shares of MDXG for 2.82 per share on Dec 22. After the transaction, the Chief Financial Officer now owns 565,206 company shares. In a previous transaction on Sep 13, Stein Robert Benjamin sold 8,329 shares at 3.46 per share. MDXG shares that President, Regenerative Med. owns now total 278,673.

Among the insiders who sold shares, Stein Robert Benjamin disposed of 19,000 shares on Sep 12 at a per-share price of $3.44. This resulted in the President, Regenerative Med. holding 287,002 shares of MDXG after the transaction. In another insider transaction, Stein Robert Benjamin sold 8,503 shares at $4.04 per share on Aug 12. Company shares held by the President, Regenerative Med. now total 306,002.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for MDXG in the last 3 months, the mean price target is $10.25 with high estimates of $16.00 and low estimates of $7.00. In terms of 52-week highs and lows, MDXG has a high of $6.35 and a low of $2.43.

As of this writing, MDXG has an earnings estimate of -$0.08 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.03 per share and a lower estimate of -$0.12. The company reported an EPS of -$0.11 in the last quarter, which was -10.00% lower than expectations of -$0.1.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 3 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MDXG is Buy with a score of 5.00. A total of 3 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles